Stay updated with breaking news from Peter salzmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immunovant (NASDAQ:IMVT – Get Rating) had its price target lifted by Chardan Capital from $21.00 to $32.00 in a report published on Monday, The Fly reports. Several other analysts also recently issued reports on the stock. Guggenheim raised shares of Immunovant from a neutral rating to a buy rating and set a $30.00 price target […] ....
Immunovant (NASDAQ:IMVT – Get Rating) had its price target increased by research analysts at HC Wainwright from $26.00 to $27.00 in a report issued on Tuesday, The Fly reports. HC Wainwright’s target price would suggest a potential upside of 27.36% from the company’s current price. Other analysts have also issued research reports about the company. […] ....
Immunovant (NASDAQ:IMVT – Get Rating) released its quarterly earnings results on Monday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.05), Briefing.com reports. Immunovant Price Performance Shares of NASDAQ IMVT traded down $0.95 during midday trading on Wednesday, reaching $21.29. 156,984 shares of the stock traded hands, compared […] ....
Immunovant (NASDAQ:IMVT – Get Rating) issued its quarterly earnings data on Monday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.05), Briefing.com reports. Immunovant Price Performance Immunovant stock traded down $0.61 during trading hours on Wednesday, hitting $21.63. The stock had a trading volume of 260,241 […] ....
Immunovant (NASDAQ:IMVT – Get Rating) had its target price increased by equities research analysts at Bank of America from $26.00 to $28.00 in a research note issued to investors on Tuesday, The Fly reports. Bank of America‘s price target points to a potential upside of 17.55% from the stock’s current price. IMVT has been the […] ....